P-gp和Topo-II在原发性肝癌中的表达及临床意义

Expression and implication of P-gp and Topo-II in hepatocellular carcinoma.

目的研究多药耐药相关蛋白P-糖蛋白(gp)和拓扑异构酶II(Topo-II)在原发性肝癌组织中的表达及临床意义。方法采用免疫组化S-P法检测49例原发性肝癌组织P-gp和Topo-II的表达。结果P-gp和Topo-II在原发性肝癌中阳性表达率分别为61.22%(30/49)和32.65%(16/49),P-gp主要在细胞膜和细胞浆中表达,Topo-II在细胞核内表达,P-gp和Topo-II表达与Edmonson分级有关,Topo-II还与转移有关。P-gp、Topo-II在原发性肝癌中表达呈负相关(P<0.05)。结论肝癌组织P-gp和Topo-II表达可能是肝癌对化疗不敏感的原因之一。

Objective To investigate the expressions of P-gp and Topo-Ⅱ in hepatocellular carcinoma（HCC） and analyze its clinical significance. Methods Forty nine histologically verified HCC specimens were examined for P-gp and Topo-Ⅱ by immunohistochemical method（sp）. Results The positive rates of P-gp and Topo-Ⅱ were 61.22%（30/49） and 32. 65% （16/49）, respectively. P-gp was expressed mainly in cytoplasmic membrane and cytoplasm and Topo-Ⅱ was restricted to cellular nucleus. The expressions of P-gp and Topo-Ⅱ had relations to histological grade. The expression of Topo-Ⅱ was also related to metastasis. The expressions of P-gp was inversely related to those of Top-Ⅱ in HCC（P〈 0. 05）. Conclusion The expression of P-gp and Topo-Ⅱ in hepatocelluar carcinoma plays an important role in chemotherapy strategy.